DC Bead – Transarterial Chemoembolisation

» DC Bead – Transarterial Chemoembolisation

Enquire about this product

  • This field is for validation purposes and should be left unchanged.

Chemoembolisation or transarterial chemoembolisation (TACE) is used in the treatment of hypervascularised malignant tumours. TACE therapy combines chemotherapy drugs with embolisation.

DC Bead is a Drug Delivery Embolisation System capable of loading and eluting the controlled release of high doses of chemotherapeutic agents.

The procedure is called Precision TACE (Transarterial Chemoembolisation) and is used in the treatment of:

  • Hepatocellular Carcinoma (HCC)
  • Colorectal Metastases (mCRC)

DC Bead is CE Marked for loading with doxorubicin (DEBDOX) and irinotecan (DEBIRI).

DC Bead Presentation

  • Novel N-fil technology sulphonate modified hydrogel polymer
  • Blue tinted to aid visualisation
  • Delivered as vials containing 2ml Beads in 6ml saline
  • Precise calibration to achieve an accurate level of embolisation

Loaded with Doxorubicin:  DEBDOX

DC Bead is intended to be loaded with doxorubicin for the purpose of:

  • Embolisation of vessels supplying malignant hypervascularised tumour(s)
  • Delivery of a local, controlled, sustained dose of doxorubicin to the tumour(s)

DEBDOX

DC Bead has been shown in multiple studies to offer benefits to patients vs conventional TACE in terms of improved response, survival and time to progression, and reduced systemic exposure.

Loaded with Irinotecan: DEBIRI

DC Bead is intended to be loaded with irinotecan for the purpose of:

  • Embolisation of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC)
  • Capable of eluting a local, controlled, sustained dose of irinotecan to hepatic metastases of colorectal cancer

DEBIRI

  • DEBIRI with DC Bead is a liver-directed therapy which is well tolerated in colorectal patients with liver-dominant metastases.
  • DEBIRI with DC Bead has been shown to offer the potential to downstage liver cancer patients to curative therapies by improving tumour response and delaying progression. By protecting healthy liver, DEBIRI with DC Bead may help reduce hepatic insufficiency, specifically steatohepatitis, and reduce morbidity at resection.
  • DEBIRI with DC Bead:
    • As a concomitant therapy with systemic chemotherapy in chemo-naive patients
    • As a neoadjuvant therapy in chemo-naive patients prior to resection
  • As a concomitant therapy with systemic chemotherapy in chemo-naive patients
  • As a neoadjuvant therapy in chemo-naive patients prior to resection

For more information please visit the BTG website.

Reviews

There are no reviews yet, would you like to submit yours

Be the first to review “DC Bead - Transarterial Chemoembolisation”